Anders Karlsson new CEO of AbSorber

Anders Karlsson has been appointed the new CEO of LinkMed’s portfolio company AbSorber. Karlsson has been COO of the company since the fall 2007. AbSorber’s former CEO Ingemar Lagerlöf, who is also CEO of LinkMed, is taking on the role of member of the board of AbSorber.

“Anders Karlsson has done an excellent job since he joined AbSorber in the fall. He demonstrated early on that he has the drive that is necessary for the company to achieve success in the complex transplantation market,” says LinkMed’s CEO, Ingemar Lagerlöf.

“My goal is to establish AbSorber as an innovative, world leading supplier in the transplantation sector. Our portfolio provides us with excellent potential to achieve this goal,” says Anders Karlsson.

Karlsson has extensive experience from the pharmaceutical industry. He has previously worked in the transplantation sector and was the CEO of Novartis in Norway.

AbSorber develops products that facilitate more successful transplantations. Today, AbSorber has one commercial product, a standardized transplantation test XM-ONE®, used to evaluate organ transplantation risk. AbSorber has entered into a global sales agreement for XM-ONE® with the U.S. medtech company BD. AbSorber is also developing an ABO column to facilitate organ transplantations between people of different blood groups and a diagnostic test that measures the occurrence of blood group antigens. The company was established in 1999 to commercialize findings from research carried out by professors Jan Holgersson and Suchitra Holgersson at the Karolinska University Hospital, in Huddinge, outside Stockholm.

LinkMed owns 42.1 percent of AbSorber.



For additional information contact:
Ingemar Lagerlöf, CEO LinkMed, tel: +46 8 508 939 93